Last updated: February 17, 2026
Overview of NDC 16714-0396
The National Drug Code (NDC) 16714-0396 corresponds to a specific pharmaceutical product. Based on available data, it is identified as Aflibercept Injection, 4 mg/0.1 mL (Eylea), approved for multiple indications including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and others.
Market Size and Demand Dynamics
Current Market Landscape
- The global ophthalmology drug market was valued at approximately $15 billion in 2022, with anti-vascular endothelial growth factor (VEGF) therapies accounting for a significant share, driven by indications like AMD, DME, and diabetic retinopathy.
- Aflibercept (Eylea) holds a dominant position within anti-VEGF agents, with sales exceeding $5 billion in 2022 globally, representing around 33% of the anti-VEGF segment.
Market Drivers
- Increasing prevalence of AMD and diabetic retinopathy, driven by aging populations and rising diabetes rates.
- Extended dosing intervals (every 8-12 weeks) versus competitors like Ranibizumab (Lucentis) and Bevacizumab (Off-label use), contributing to patient adherence and physician preference.
- Preference for established therapies with proven efficacy and safety profiles.
Market Challenges
- Pricing pressures from payers aiming to reduce healthcare costs.
- Entry of biosimilars and generic versions resulting in price erosion.
- Regulatory and reimbursement policies impacting drug accessibility, particularly in the U.S. and Europe.
Competitive Landscape
| Product |
Indication |
Annual Sales (2022) |
Price per Dose (Estimate) |
Market Share |
| Eylea (Aflibercept) |
AMD, DME, RVO |
~$5 billion |
$1,900 - $2,500 |
~50% of anti-VEGF market |
| Lucentis (Ranibizumab) |
AMD, DME |
~$3 billion |
$1,800 - $2,200 |
~30% of anti-VEGF market |
| Bevacizumab (Off-label) |
AMD, DME |
~$700 million |
<$800 |
~20% of anti-VEGF market |
Pricing Trends and Projections
Historical Pricing Trends
- Average price per injection: Ranged between $1,800 and $2,200 for Eylea in 2022.
- Reimbursement pressure: Aim to reduce average reimbursement to below $2,000 per dose, impacting pricing strategies.
- Market penetration: Established therapy with consistent pricing, with minimal discounts reported in the US.
Future Price Projections (2023-2027)
| Year |
Estimated Price/Injection |
Rationale |
| 2023 |
$1,900 - $2,200 |
Stable market with minor discounts; inflationary cost pressures influence pricing. |
| 2024 |
$1,850 - $2,150 |
Increased biosimilar competition may lead to slight price reductions. |
| 2025 |
$1,800 - $2,100 |
Biosimilars and generics gain market share; price erosion continues. |
| 2026 |
$1,750 - $2,050 |
Price adjustments to maintain market share; reimbursement pressures persist. |
| 2027 |
$1,700 - $2,000 |
Enhanced biosimilar presence reduces median price; pricing strategies focus on volume. |
Market Entry and Biosimilar Impact
- Biosimilars of aflibercept are in early development stages, with potential for approval by 2025.
- Biosimilar versions could reduce prices by 20-30%, impacting Eylea's market share.
- Patent expirations and biosimilar entry may prompt price reductions ahead.
Pricing and Market Strategy Implications
- Pharmaceutical companies primed to maintain competitiveness may adopt tiered pricing strategies, including discounts and value-based pricing.
- Payers will continue to negotiate for lower prices, influencing commercialization efforts.
- Developers of biosimilars are positioned to capture significant market share, especially in price-sensitive markets like Europe and emerging economies.
Regulatory and Policy Impact
- U.S. FDA approvals of biosimilars are expected to accelerate in 2024-2025.
- European regulators may approve biosimilars sooner, impacting global pricing.
- Price controls in healthcare systems such as the UK NHS and German G-BA influence market prices.
Key Takeaways
- NDC 16714-0396 (Aflibercept) dominates anti-VEGF therapy market, with patient demand driven by prevalent retinal conditions.
- Current price per dose in the U.S. averages between $1,900 and $2,200; future stabilization is likely with potential reductions driven by biosimilars.
- Biosimilar competition could reduce prices by 20-30% within the next 2-3 years.
- Market share remains high due to product efficacy, but pricing pressures and regulatory policies will influence future revenues.
- Strategic responses include tiered pricing and early biosimilar adoption to optimize market position.
FAQs
1. How will biosimilar entrants affect the pricing of NDC 16714-0396?
Biosimilars can reduce price points by 20-30%, forcing original brand prices downward and pressuring margins.
2. What is the outlook for demand for aflibercept in emerging markets?
Demand is expected to grow due to increasing prevalence of retinal diseases and expanding healthcare access, but price sensitivity may limit revenue growth compared to mature markets.
3. Are there policy measures that could stabilize prices for aflibercept?
Price regulation, inflation adjustments, and reimbursement constraints could stabilize or lower prices, especially within publicly funded healthcare systems.
4. Which indications are most commercially significant for aflibercept?
Wet AMD remains the most significant indication, constituting over 70% of sales in recent years, followed by DME.
5. How have recent patent expirations impacted market competition?
Patent expirations in 2023-2024 open the market to biosimilar competition, likely accelerating price declines and market share redistribution.
Citations
[1] IQVIA, "Global Ophthalmology Market Report," 2022.
[2] EvaluatePharma, "Anti-VEGF Market Data," 2022.
[3] U.S. FDA, "Biosimilar Approvals," 2023.
[4] MarketWatch, "Price Trends in Ophthalmology Drugs," 2022.
[5] NICE Guidelines, "Retinal Disease Treatment," 2023.
